Stanford University
Showing 11-20 of 130 Results
-
Glaivy Batsuli, MD
Associate Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsHemophilia is a rare inherited X-linked bleeding disorder characterized by the deficiency of blood clotting proteins factor VIII or factor IX. These individuals are at risk for spontaneous bleeds and trauma or surgery-induced bleeding. There have been remarkable advancements in the management of hemophilia to prevent these bleeding episodes and improve quality of life. However, the presence of neutralizing antibodies, called inhibitors, still dictates access to novel therapies such as factor replacement for bleed management and now FDA-approved gene therapies. The Batsuli Lab is focused on elucidating mechanisms of the immune response to blood coagulation proteins in bleeding disorders in order to develop strategies and therapeutics for inhibitor prevention and tolerance induction.
Dr. Batsuli's clinical research interests also include clinical trial participation for novel therapeutics & interventions in bleeding disorders such as hemophilia and von Willebrand disease in addition to coagulation issues & outcomes in ultra-rare bleeding disorders and sickle cell disease. -
Xi Ying Amanda Chen
Postdoctoral Scholar, Stem Cell Transplantation
BioDr. Chen completed a Bachelor of Science (Honours) at the University of Sydney (NSW, Australia), with majors in Molecular Biology and Immunobiology. She graduated with the University Medal for her Honours research project where she investigated the novel role of DNA damage repair machinery on telomerase recruitment to telomeres. She then undertook her graduate studies at the Peter MacCallum Cancer Centre (The University of Melbourne, VIC, Australia) in the Beavis laboratory, where she developed a CRISPR knock-in strategy to engineer armored CAR T cells to express therapeutic payloads in a tumor-restricted manner. She joined the Porteus laboratory in the Department of Pediatrics at Stanford University in March 2025, where she is developing strategies to enhance gene-edited hematopoietic stem cell transplantation.
